Skip to main content
. Author manuscript; available in PMC: 2013 Aug 7.
Published in final edited form as: Liver Transpl. 2011 May;17(5):528–538. doi: 10.1002/lt.22271

Figure 1.

Figure 1

Overview of the study and its subjects. Patients were randomized 10 to 26 weeks post-LT to receive peginterferon alfa-2a/ribavirin therapy either prophylactically or upon observation of HCV recurrence. The study duration was 120 weeks: prophylaxis patients received 48 weeks of treatment and 72 weeks of follow-up, observation patients who received no treatment received 48 weeks of observation and 72 weeks of follow-up, and observation patients who switched to treatment received 0 to 48 weeks of observation followed by 48 weeks of treatment and 24 to 72 weeks of follow-up.